Glenmark Life Sciences Ltd - 543322 - Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 48111 Name of the Signatory :- Rudalf CorrieaDesignation :- Company Secretary and Compliance Officer Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Pursuant to Regulation 32(6) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 read with Regulation 41(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, we are enclosing herewith Monitoring Agency Report dated November 12, 2021 issued by HDFC Bank Limited, Monitoring Agency, for the quarter ended 30th September, 2021 in respect of utilization of proceeds of the IPO of the Company. This is for your information and record. Q2FY22 Quarterly Result Announced for Glenmark Life Sciences Ltd.
Highlights: For the second quarter of FY22, GLS registered revenue from operations of Rs. 5,617.6 Mn, recording a YoY growth of 7.9%. Revenues from the Generic API segment increased 3.9% YoY to Rs. 5,046.7 Mn during the quarter whereas CDMO grew by 85.1% to Rs. 490.4 Mn. Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA) was at Rs. 1,694.3 Mn for the second quarter growing at 33.5% YoY. EBITDA margin for the quarter was 30.2%. Profit After Tax (PAT) was at Rs. 1,152.0 Mn, registering a growth of 59.0% against the corresponding quarter of the previous financial year. The company declared an interim dividend of Rs. 10.5 per share (face value Rs. 2) Commenting on the company’s performance Dr. Yasir Rawjee, MD & CEO, Glenmark Life Sciences Limited said, “At Glenmark Life Sciences, both our generic API business and CDMO business have delivered growth for the quarter ended September 30, 2021, fuelled by demand in key regulated markets. We are delighted that the CDMO business has picked up pace this quarter. We will continue to remain focused on our growth levers for sustainable long term growth.” Dr. Rawjee further added “We are also on track to cater to the growing demand through strategic investments in brownfield expansion at our Dahej facility and a modern green-field manufacturing facility at Solapur. Going forward, we will continue to deliver on quality, safety and environmental compliance which form the bedrock for our company.” According to Bhavesh Pujara, CFO, Glenmark Life Sciences Limited, “Our results for the quarter reinforce continued growth momentum in our top line leading to a robust 18.4% growth in H1 of FY22. Despite multiple headwinds coming from spike in input prices, logistics costs and energy prices, we have sustained healthy EBITDA margin of 30.2% for the quarter. We intend to stay on course in maintaining our profitability and returns through productivity improvement, cost discipline and efficient next generation processes while we execute our strategic plans for our future growth drivers” Result PDF Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Investor Presentation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the investor presentation. Glenmark Life Sciences Ltd - 543322 - Board declares Interim Dividend
Glenmark Life Sciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on November 11, 2021, inter alia, has declared an interim dividend of Rs. 10.5/- per equity share of face value of Rs. 2/- each forthe financial year ending March 31, 2022. Glenmark Life Sciences Ltd - 543322 - Fixes Record Date For The Interim Dividend - 23Rd November, 2021
The Board declared an interim dividend of Rs.10.5/-per equity share of face value of Rs.2/ each for the financial year ending 31st March, 2022. Record date for the purpose of determining the entitlement of the shareholders for the interim dividend has been fixed as 23rd, November 2021, and dividend will be paid to the shareholders on or after 3rd December, 2021. Glenmark Life Sciences Ltd - 543322 - Outcome Of The Board Meeting -10Th November, 2021
The Board of Directors of Glenmark Life Sciences Limited at its meeting held on November 10, 2021, has, inter alia, considered and approved: Financial Result: 1. The Unaudited Financial Results for the Second Quarter and Half Year ended September 30, 2021 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The copy of the said results together with Management Discussion & Analysis, Press Release and Limited Review Report of the Auditors is enclosed herewith. These are also being made available on the website of the Company at www.glenmarkllfesciences.com Interim Dividend: 2. Declared an interim dividend of Rs. 10.5/-per equity share of face value of Rs.2/ each for the financial year ending 31st March, 2022. Record date for the purpose of determining the entitlement of the shareholders for the interim dividend has been fixed as 23rd, November 2021, and dividend will be paid to the shareholders on or after 3rd December, 2021. Glenmark Life Sciences Ltd - 543322 - Corporate Action-Board to consider Dividend
In continuation to our Board meeting intimation dated November 1, 2021 and pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company at its meeting scheduled to be held on Wednesday, November 10, 2021 will also consider proposal for payment of interim Dividend to members of the Company for the Financial year 2021-22. Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Enclosed please find herewith the details of Earnings Call slated for Thursday, November 11, 2021 at 8:30 a.m. - 9:30 a.m. (IST), for your information and record. Please note that the recording of the call will be available on our website within 24 hours of the call. Glenmark Life Sciences Ltd - 543322 - Minutes Of The Resolution Passed By Way Of Postal Ballot Through Remote E-Voting Process
Minutes of the Resolution passed by way of Postal Ballot through remote e-voting process